**Name of Journal: *World Journal of Nephrology***

**Manuscript NO: 31294**

**Manuscript Type: Original Article**

***Retrospective Study***

**Reproducibility of serial creatinine excretion measurements in peritoneal dialysis**

Xu Z *et al*. Creatinine excretion in PD

**Xu Zhi, Glen H Murata, Yijuan Sun, Robert H Glew, Clifford Qualls, Darlene Vigil, Karen S Servilla, Thomas A Golper, Antonios H Tzamaloukas**

**Xu Zhi**, Nephrology Division, Department of Medicine, University of New Mexico School of Medicine, Albuquerque, NM 87131, United States

**Glen H Murata**, **Clifford Qualls,** Research Service, Raymond G Murphy Veterans Affairs Medical Center, Albuquerque, NM 87108, United States

**Yijuan Sun**, **Darlene Vigil**, **Karen S Servilla,** Renal Section, Medicine Service, Raymond G. Murphy VA Medical Center and Department of Medicine, University of New Mexico School of Medicine, Albuquerque, NM 87108, United States

**Robert H Glew**, Department of Surgery, University of New Mexico School of Medicine, Albuquerque, NM 87131, United States

**Thomas A Golper**, Division of Nephrology and Hypertension, Vanderbilt University, Nashville, TN 37212, United States

**Antonios H Tzamaloukas**, Renal Section and Research Service, Raymond G. Murphy VA Medical Center and Department of Medicine, University of New Mexico School of Medicine, Albuquerque, NM 87108, United States

**Author contributions:** Xu Z composed the largest part of the first draft of this report; Murata GH was responsible for part of the statistical analysis and made critical changes in the report; Sun Y assisted in the data collection and made critical changes in this report; Glew RH made critical changes in the manuscript; Qualls C was responsible for part of the statistical analysis; Vigil D made important changes in this report; Servilla KS assisted in the data collection and made important changes in the manuscript; Golper TA conceived the study and made critical changes in the report; Tzamaloukas AH designed the study, assisted in the collection of data and wrote parts of the report.

**Institutional review board statement**: This study was reviewed and approved by the Human Research Committee of the Raymond G. Murphy VA Medical Center.

**Informed consent statement**: Patients were not required to give informed consent to this retrospective study because the study used anonymous clinical data obtained to evaluate adequacy of dialytic treatment. Each patient has agreed to the dialytic treatment and the collection of the data used in the study. The institutional Human Research Committee approved the use of these data for this study without a signed informed consent.

**Conflict-of-interest statement**: We have no financial relationships to disclose.

**Data sharing statement**: No additional data are available.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Correspondence to:** **Antonios H Tzamaloukas, MD, MACP, Physician,** Renal Section and Research Service, Raymond G. Murphy VA Medical Center and Department of Medicine, University of New Mexico School of Medicine, 1501 San Pedro, SE, Albuquerque, NM 87108, United States. antonios.tzamaloukas@va.gov

**Telephone:** +1-505-2651711-4733

**Fax:** +1-505-2566441

**Received:** November 8, 2017

**Peer-review started:** November 10, 2017

**First decision:** March 8, 2017

**Revised:** March 21, 2017

**Accepted:** May 3, 2017

**Article in press:**

**Published online:**

**Abstract**

***AIM***

To test whether muscle mass evaluated by creatinine excretion(EXCr) is maintained in patients with end-stage kidney disease (ESKD) treated by peritoneal dialysis (PD), we evaluated repeated measurements of EXCr in a PD population.

***METHODS***

One hundred and sixty-six PD patients (94 male, 72 female) receiving the same PD dose for the duration of the study (up to approximately 2.5 years) had repeated determinations of total (in urine plus spent dialysate) 24-h EXCr (EXCr T) to assess the adequacy of PD by creatinine clearance. All 166 patients had two EXCr T determinations, 84 of the 166 patients had three EXCr T determinations and 44 of the 166 patients had four EXCr T measurements. EXCr T values were compared using the paired t test in the patients who had two studies and by repeated measures ANOVA in those who were studied three or four times.

***RESULTS***

In patients who were studied twice, with the first and second EXCr T measurements performed at 9.2 ± 15.2 mo and 17.4 ± 15.8 mo after onset of PD, respectively, EXCr T did not differ between the first and second study. In patients studied three times and whose final assessment occurred 24.7 ± 16.3 mo after initiating PD, EXCr T did not differ between the first and second study, but was significantly lower in the third study compared to the first study. In patients who were studied four times and whose fourth measurement was taken 31.9 ± 16.8 mo after onset of PD, EXCr T did not differ between any of the studies. The average EXCr T value did not change significantly, with the exception of the third study in the patients studied thrice. However, repeated determinations of EXCr T in individuals showed substantial variability, with approximately 50% of the repeated determinations being higher or lower than the first determination by 15% or more.

***CONCLUSION***

The average value of EXCr Tremains relatively constant for up to 2.5 years of follow-up in PD patients who adhere to the same PD schedule. However, repeated individual EXCr T values vary considerably in a large proportion of the patients. Further studies are needed to evaluate the clinical significance of varying EXCr T values and the stability of EXCr T beyond 2.5 years of PD follow-up.

**Key words:** Creatinine excretion; Muscle mass; Peritoneal dialysis; Lean body mass

**© The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Totalcreatinine excretion (EXCr) in urine and in the used peritoneal dialysis (PD) fluid is correlated with muscle mass and has been shown to predict survival and morbidity of patients on PD. This retrospective study evaluated the long-term constancy of 24-h excretion of creatinine in urine and spent peritoneal dialysate from patients with end-stage kidney disease treated by PD. Over a period of 2.5 years, the average value of total EXCr in the study population did not change significantly. However, in individuals there was a substantial variation of repeated measurements of total EXCr above or below its initial value. Approximately half of those studied repeatedly exhibited total EXCr above or below its initial value. Further studies are needed to evaluate changes, both increase and decrease, of EXCr in PD patients and the constancy of EXCr in patients on PD for more than 2.5 years.

Xu Z, Murata GH, Sun Y, Glew RH, Qualls C, Vigil D, Servilla KS, Golper TA, Tzamaloukas AH. Reproducibility of serial creatinine excretion measurements in peritoneal dialysis. *World J Nephrol* 2017; In press

**INTRODUCTION**

An elevated serum creatinine concentration ([Cr]S) is a predictor of prolonged survival in patients undergoing chronic peritoneal dialysis (PD)[1]. [Cr]S is largely a function of muscle mass and is widely regarded as a reliable indicator of somatic nutrition. Exercising muscles secrete a variety of myokines with beneficial effects on various organ systems, including anti-inflammatory effects[2]. Physical inactivity leads to altered pattern of myocyte secretion promoting obesity and atherogenesis[2]. Inactivity is prominent among patients treated by chronic dialysis. McIntyre and collaborators reported a tendency to muscle mass depletion in this patient group[3]. However, a significant limitation of [Cr]S as an indicator of somatic nutrition is reliance on this parameter as the sole determinant of muscle mass.In the steady state, which is defined as equal rates of creatinine production and elimination, [Cr]S has two physiological determinants, the rate of production of creatinine (PCr) which is a function of muscle mass, and the rate of removal of creatinine from body fluids, which is expressed as creatinine clearance (CCr). This relation is expressed as [Cr]S = PCr/CCr. Consequently, variations in CCr in patients on PD can result in variations in [Cr]S that are unrelated to muscle mass[4].

In the steady state, the total amount of creatinine excreted in spent PD dialysate plus urine over a certain time period (EXCr T) is in general a better index of muscle mass than [Cr]S. Conditions in which EXCr T does not reflect muscle mass are addressed in the Discussion section of this report. EXCr Tover 24 h was been proposed by Walser[5] as an index of somatic nutrition in the general adult population and has been evaluated in PD populations. Whereas high EXCr T values are associated with favorable outcomes, including survival and continued success of PD[6,7], low values of EXCr T are associated with a high risk of peritonitis and PD catheter-related infections[8].

The lean body mass formula from creatinine production (LBMCr) in PD patients[9] takes into account EXCr T and creatinine eliminated though metabolic creatinine degradation (MCD), the second variable at a clearance of 0.038 L/kg[10]. MCD per 24-h is calculated as 0.038$×$[Cr]S$(\frac{mg}{dL})×$10$×$Weight(kg). EXCr T is invariably the larger of the two determinants of LBMCr. For example, in a 53-year old PD patient who weighs 70 kg and has a [Cr]S value of 9.5 mg/dL, estimated MCD rate will be 253 mg/24-h. Applying a PD population-specific formula predicting EXCr T[11] to this illustrative example, average estimates of EXCr T, in mg/24-h, are 1062 if the patient is male and non-diabetic, 1023 if the patient is male and diabetic, 892 if the patient is female and non-diabetic and 852 if the patient is female and diabetic. High LBMCr values predict long survival of PD patients[12-14].

The short-term reproducibility of EXCr T in PD was studied by Lo and coauthors, who obtained two to four 24-h collections of urine and spent dialysate over a one-week interval from five patients undergoing PD[15]. These authors reported maximal variations of EXCr T from the mean ranging between 0.32% and 19.88%. The purpose of the present study was to investigate the reproducibility of EXCr T in patients on long-term PD. Changes in renal function or peritoneal transport characteristics will change the amount of creatinine removed through each route. However, regardless of such changes steady state long-term constancy of EXCr T is consistent with preservation of muscle mass in PD patients. In contrast, a progressive decrease in EXCr T during PD would indicate progressive loss of muscle mass and deterioration of somatic nutrition.

**MATERIALS AND METHODS**

We analyzed creatinine excretion data collected during routine clearance measurements for assessment of the adequacy of PD. Patients included in this study were followed in Albuquerque during the years 1992 to 2002. Only patients in whom the prescribed dose of PD did not change during the observation period were included in the study. Approximately 40% of the patients were receiving continuous ambulatory peritoneal dialysis (CAPD) with four or five daily exchanges and 2.0-L or 2.5-L fill volume. The remaining patients received nocturnal automatic PD with 8-10 L fill volume plus one or two daytime PD exchanges with 2.0 L fill volume. Serum ([Cr]S) at the study differed from the preceding or following monthly value by < 0.30 mg/dL in all patients. None of the patients were receiving drugs causing increased creatinine production (*e.g.*, fenofibrate).

The focus of the study was on detecting a statistically significant decline in EXCr T. The minimal number of patients required to detect a 15% reduction in EXCr T over time was calculated by power analysis. For a simple power analysis, we considered repeated measurements at two points in time and assumed a correlation of 0.7 between these two samples and a standard deviation of EXCr T equal to 450 mg/24-h (see Tables in Results). The power and α value of the study were set at 80% and 0.05 respectively.

Between the sequential clearance studies we compared the following variables: Urine volume (VU), drain volume (VD), weekly Kt/V urea, weekly CCr,serum urea nitrogen level (SUN), [Cr]S, EXCr in urine (EXCr U), EXCr in dialysate (EXCr D),and total creatinine excretion in urine plus dialysate (EXCr T).

***Statistical analysis***

Results are reported as mean ± SD. Statistical comparisons were carried out using the two-tailed paired *t* test for patients with two clearance studies and the repeated measures ANOVA for patients who had three or four clearance studies. Statistical analysis was performed using SAS version 9.4.

**RESULTS**

Power analysis computed a minimal sample size of 37 patients for detecting a 15% decline in EXCr T. A total of 166 PD patients who had been subjected to at least two clearance studies comprised the initial study group. Among these patients, 84 patients had three clearance studies and 44 patients had four clearance studies. Small number of patients, eight or less, underwent five or more studies. Consequently, this study includes patients who had two, three and four clearance studies.

Table 1 summarizes relevant features of the patients included in the report. There were no significant differences between the three subgroups in terms of the age of patients at the onset of PD, percent of males and females or percent of patients with end-stage renal disease secondary to diabetic nephropathy.

 Table 2 compares variables related to creatinine excretion in patients with two clearance studies. Between the first and second clearance study VU, total Kt/V urea, total CCr, and EXCr U decreased, [Cr]S and EXCr D increased, while VD, SUN and EXCr T did not change significantly. Peritoneal CCr did not change while renal CCr decreased from the first to the second study. Average peritoneal (CCr P) and renal (CCr R) weekly CCr, expressed in L/1.73 m2 thoughout this report, values were as follows: CCr P 48.7 in the first and 49.5 in thesecond study; CCr R 29.1 in the first and 18.4 in the second study.

Table 3 compares variables in patients who were studied three times. VU, total Kt/V urea, total CCr and EXCr U decreased progressively from the first to the third measurement, while EXCr T was significantly lower in the third study than in the first study. VD and SUN did not change, while [Cr]S increased; however, the increasing trend in EXCr D did not reach statistical significance. Peritoneal CCr did not change while renal CCr decreased progressively from the first to the third study. Average weekly CCr P and CCr R values were as follows: CCr P 50.5 in the first, 48.2 in the second and 49.7 in the third study; CCr R 28.8 in the first, 23.2 in the second and 18.3 L/1.73 m2 in the thirst study.

Table 4 compares clearances and creatinine excretion parameters in patients who had four clearance studies. VU, total Kt/V urea and total CCr decreased progressively from the first to the fourth determination. EXCr U decreased significantly between the first and third studies, but reached a stable mean between the third and fourth studies. [Cr]S increased progressively from the first to the third study; however, the mean values were not different between in the third and fourth studies. VD and SUN were essentially the same in the four studies. EXCr D increased progressively from the first to the fourth study, whereas EXCr T did not change significantly throughout the study. Peritoneal CCr did not change while renal CCr decreased progressively from the first to the fourth study. Average weekly CCr P and CCr R values were as follows: CCr P 50.2 in the first, 47.4 in the second, 51.2 in the third and 49.7 in the fourth study; CCr R 27.3 in the first, 23.0 in the second, 17.3 in the thirst and 16.4 L/1.73 m2 in the fourth study.

Table 5 shows the results (number and percent) of the second, third and fourth studies where EXCr T differed from the EXCr T of the first study by less than 15%. The same table also shows the number and percent of studies with EXCr T higher or lower than the EXCr T of the first study by 15% or more. In approximately half of the second, third and fourth studies EXCr T differed from the first study by less than 15%. In 25.0%-33.3% of the patients, EXCr T values in subsequent studies were higher than the EXCr T value found in the first study by more than 15%. In 19.1%-21.1% of the patients, EXCr T in subsequent studies was lower than the EXCr T in the first study by more than 15%.

**DISCUSSION**

This study had two important findings: First the mean EXCr T value did not change significantly in 2.5 years of follow-up of patients who were on the same PD schedule for the duration of the study, with the exception of a lower mean EXCr T in the third study than in the first study in EXCr data analyzed thrice. The constancy of the mean EXCr T was maintained despite a progressive decrease in urinary volume, urinary CCr and urinary EXCr. Increases in peritoneal EXCr associated with parallel rises in [Cr]S offset the declines in renal EXCr. Second, in about half of the patients, individual values of EXCr T varied substantially in clearance studies following the initial study. These findings have important clinical implications.

The finding of unchanged EXCr T suggests that the muscle mass of the average patient who remains on PD for 2.5 years is preserved. This observation points to stable creatinine production, and preserved muscle mass, as favorable predictors of outcomes of PD; however, this issue will require further investigation. The finding of great variation of individual EXCr T values on repeated measurements should prompt investigation of the factors affecting EXCr T in PD in addition to changes in the muscle mass.

One factor that can affect EXCr T is a change in total CCr. Mitch and Walser computed a “metabolic” CCr equal to 0.038 L/kg per 24-h in patients with renal failure mediated primarily by creatinine elimination through the gastrointestinal tract[16]. As [Cr]S levels increase progressively in advancing renal failure, the amount of creatinine removed through the metabolic-route increases progressively with a concomitant decrease in the measured renal EXCr[16].

Large increases in total CCr in PD patients lead in the steady state to drop in [Cr]S and in creatinine removal by the “metabolic” route and increase in ExCr T. In a previous study, we noted an increase in EXCr T in PD patients whose measured total (peritoneal plus renal) CCr was increased, with proportional decrease in [Cr]S, following prescribed increases in the PD dose[17]. This was the reason for including in the present study only patients with unchanged PD schedules. No effect of the decrease in total CCr through loss of renal function on EXCr T was seen in this study even when total CCr decreased by 11.4 L/1.73 m2 weekly, on the average, between the first and fourth measurements (Table 4). We suggest that the increase in the amount of creatinine removed by the metabolic route due to the rise in [Cr]S between these two measurements was too small to be detected by our statistical analysis. On average, [Cr]S rose by 1.0 mg/dL between the first and fourth clearance study (Table 4). With this degree of increase in [Cr]S, the rise in the amount of creatinine removed through the metabolic route at a CCr of 0.038 L/kg per 24-h would be only 26.6 mg/24-h in an individual weighing 70 kg.

Creatinine is formed by non-enzymatic breakdown of creatine-phosphate. Variations in the rate of creatine-phosphate conversion to creatinine may cause changes in EXCr T that are independent of changes in muscle mass. Neuromuscular diseases[18] and the stage of recovery from protein malnutrition[19] are examples of conditions characterized by abnormal creatine metabolism which leads to dissociation between creatinine production and muscle mass. In addition, neuromuscular diseases affect creatinine production and excretion through their effect on muscle mass homeostasis. The loss of muscle mass secondary to chronic neuromuscular disease is one of the major causes of decreases in creatinine production and EXCr T. Acute muscular disease, (*e.g.*, rhabdomyolysis) however, increases creatinine production. Rhabdomyolysis can result from disease, poisons and medications exemplified by lipid-lowering agents[20]. Other conditions causing increases in creatinine production and EXCr T include pregnancy[21], consumption of meat and intense exercise[22].

Circumstances that raise EXCr T without affecting creatinine production include errors in the collection of urine and spent dialysate and the presence of a non-steady state. Non-steady state following a rapid rise in CCr will increase EXCr T and decrease [Cr]S. A hemodialysis session represents such a non-steady state condition. PD patients, who are non-compliant with their PD prescription and resume the prescribed PD schedule on the day of a clearance study will manifest a similar non-steady state. A high value of measured EXCr T over the EXCr T predicted by the Cockroft-Gault formula[23] (M/PCr) was proposed as a means of identifying non-compliance in PD[24]. Although some studies supported the use of the M/PCr ratio as a means of detecting PD non-compliance[25,26],several reports confirmed that the sensitivity of this test is poor[27-32]. Nevertheless, noncompliance will invariably increase EXCr T on the first day of resumption of the prescribed PD schedule[28] and can be an important cause of the variation of EXCr T.

Conditions that can potentially lead to low EXCr T values include decreased production of creatinine, urine and dialysate collection errors, and intercurrent acute illnesses. This last category has not been studied adequately in PD patients. In acute illness, creatinine production could be temporally increased because of muscle disease or decreased because of loss of muscle mass. In one study, PD-associated peritonitis with routine course resulted in a 2.3% drop in body weight and 7.8% drop in [Cr]S, while peritonitis with a protracted course resulted in a 7.2% drop in body weight and 25.0% drop in [Cr]S[33]. These findings suggest a loss of muscle mass proportional to the duration of peritonitis. However, an increase in peritoneal CCr secondary to peritoneal membrane inflammation could also cause a drop in [Cr]S. EXCr data, which would allow differentiation between a rise in CCr and a loss of muscle mass as the cause of the decrease in [Cr]S were not provided in this study. The effects of acute illness on EXCr in PD will need further studies.

A final consequence of all the aforementioned influences on EXCr T is their effect on the estimation of LBMCr. Two studies reported agreement between LBMCr and estimation of lean body mass by research methodologies[34,35]. Another study suggested that determination of lean body mass as LBMCr has advantages over its determination by bioimpedance or dual energy X-ray absorptiometry in overhydrated PD patients[36]. However, several studies have reported substantial differences between LBMCr and other methods used to assess muscle mass and between LBMCr and other indices of nutrition in PD patients[35,37-42]. Nevertheless, one of these studies did support the monitoring of EXCr T as a means of assessing changes in muscle mass[37].

Our study has limitations: First, selection bias could have led to the finding of stable creatinine excretion with stable patients remaining on PD for longer time. Related to this limitation, clinical information and data on other indices of nutrition associated with the observed changes in EXCr T were not available for analysis. Second, the data available to us do not allow us to address whether any of the known determinants of creatinine excretion in patients treated by PD (body weight, age, gender, and diabetic status) can predict a decrease or increase in their EXCr T. Finally, monitoring of EXCr T beyond 2.5 years after initiation of PD was not performed because of the small number of such subjects. Future studies should address these limitations.

In conclusion, average EXCr T remains stable for up to 2.5 years in patients who are maintained on the same PD schedule, despite a progressive loss of residual renal function which causes a progressive decline in urinary flow rate, CCr and EXCr. This finding suggests that the muscle mass of the average patient who remains on PD during this same time period is preserved. However, many patients exhibit substantial variability of EXCr T in sequential measurements. Both increases and decreases in EXCr T of individual patients managed by PD call for a systematic search for the conditions responsible for these changes. Further studies are also needed to evaluate the stability of EXCr T beyond 2.5 years of PD and the potential associations of changes in EXCr T with clinical outcomes and other indices of nutrition.

**ACKNOWLEDGEMENTS**

We thank the Research Service of the Raymond G. Murphy VA Medical Center for clerical and administrative support of this study.

**COMMENTS**

***Background***

In the steady state, defined as equal rates of production and removal, creatinine excretion reflects muscle mass. Loss of muscle mass has adverse effects on the outcomes of patients with chronic diseases, including patients with end-stage kidney disease treated by peritoneal dialysis (PD). High levels of creatinine excretion are associated with favorable outcomes in this patient population. The prevalence of adverse influences (*e.g.*, inactivity, chronic inflammatory state) in PD populations suggests loss of muscle mass in long-term PD. Repeated measurement of creatinine excretion in patients on long-term PD, which represents a steady state, provide a means of monitoring muscle mass.

***Research frontiers***

Muscle mass can be evaluated by several research methods. These methods require expenses and added expertise of the research personnel and, therefore, are not suitable for routine monitoring of PD populations.

***Innovations and breakthroughs***

Repeated measuring of total excretion of creatinine in spent peritoneal dialysate and urine offers a way of monitoring muscle mass in PD patients. Creatinine excretion measurements have been performed as part of monitoring adequacy of azotemic indices removal in PD. Comparison of subsequent creatinine excretion measurements to the first measurement, as used in this study, is simple and does not require added expenses.

***Applications***

The methodology explored in this report is appropriate for monitoring patients on long-term PD and for evaluating interventions (*e.g.*, exercise, diet) directed towards preserving or improving muscle mass in these patients.

***Terminology***

The following abbreviations express the technique for monitoring creatinine excretion in PD: ExCr U = urinary creatinine excretion, mg/24-h; ExCr D = creatinine excretion in spent peritoneal dialysate, mg/24h; ExCr T = ExCr U + ExCr D.

***Peer-review***

In this manuscript, the authors describe the reproducibility of serial creatinine excretion measurements in peritoneal dialysis (PD) patients. They concluded that the average total creatinine excretion in urine plus dialysate (EXcr T) remains stable for up to 2.5 years in patients who are maintained on the same PD schedule, despite the progressive loss of residual renal function which causes a progressive decline in the urinary flow rate, renal plus peritoneal creatinine clearance (Ccr), and creatinine excretion (EXcr). They also suggested that the muscle mass was preserved in the average patient who remained on PD during this time period. This paper is clinically interesting.

**REFERENCES**

1 **Park J**, Mehrotra R, Rhee CM, Molnar MZ, Lukowsky LR, Patel SS, Nissenson AR, Kopple JD, Kovesdy CP, Kalantar-Zadeh K. Serum creatinine level, a surrogate of muscle mass, predicts mortality in peritoneal dialysis patients. *Nephrol Dial Transplant* 2013; **28**: 2146-2155 [PMID: 23743018 DOI: 10.1093/ndt/gft213]

2 **Pedersen BK**, Febbraio MA. Muscles, exercise and obesity: skeletal muscle as a secretory organ. *Nat Rev Endocrinol* 2012; **8**: 457-465 [PMID: 22473333 DOI: 10.1038/nrendo.2012.49]

3 **McIntyre CW**, Selby NM, Sigrist M, Pearce LE, Mercer TH, Naish PF. Patients receiving maintenance dialysis have more severe functionally significant skeletal muscle wasting than patients with dialysis-independent chronic kidney disease. *Nephrol Dial Transplant* 2006; **21**: 2210-2216 [PMID: 16504974 DOI: 10.1093/ndt/gfl064]

4 **Tzamaloukas AH**, Murata GH, Piraino B, Rao P, Bernardini J, Malhotra D, Oreopoulos DG. Peritoneal urea and creatinine clearances in continuous peritoneal dialysis patients with different types of peritoneal solute transport. *Kidney Int* 1998; **53**: 1405-1411 [PMID: 9573559 DOI: 10.1046/j.1523-1755.1998.00896.x]

5 **Walser M**. Creatinine excretion as a measure of protein nutrition in adults of varying age. *JPEN J Parenter Enteral Nutr* 1987; **11**: 73S-78S [PMID: 3312696 DOI: 10.1177/014860718701100510]

6 **Jager KJ**, Merkus MP, Dekker FW, Boeschoten EW, Tijssen JG, Stevens P, Bos WJ, Krediet RT. Mortality and technique failure in patients starting chronic peritoneal dialysis: results of The Netherlands Cooperative Study on the Adequacy of Dialysis. NECOSAD Study Group. *Kidney Int* 1999; **55**: 1476-1485 [PMID: 10201013 DOI: 10.1046/j.1523-1755.1999.00353.x]

7 **Perez RA**, Blake PG, Spanner E, Patel M, McMurray S, Heidenheim P, Lindsay RM. High creatinine excretion ratio predicts a good outcome in peritoneal dialysis patients. *Am J Kidney Dis* 2000; **36**: 362-367 [PMID: 10922315 DOI: 10.053/ajkd.2000.8987]

8 **Wu CH**, Huang CC, Wu MS, Yang CW, Huang JY, Fang JT, Leu ML. Total creatinine appearance as indicator of risk of infectious complication in peritoneal dialysis. *Adv Perit Dial* 2000; **16**: 219-222 [PMID: 11045298]

9 **Keshaviah PR**, Nolph KD, Moore HL, Prowant B, Emerson PF, Meyer M, Twardowski ZJ, Khanna R, Ponferrada L, Collins A. Lean body mass estimation by creatinine kinetics. *J Am Soc Nephrol* 1994; **4**: 1475-1485 [PMID: 8161729]

10 **Mitch WE**, Collier VU, Walser M. Creatinine metabolism in chronic renal failure. *Clin Sci (Lond)* 1980; **58**: 327-335 [PMID: 7379458 DOI: 10.1042/cs0580327]

11 **Tzamaloukas AH**, Murata GH. A population-specific formula predicting creatinine excretion in continuous peritoneal dialysis. *Perit Dial Int* 2002; **22**: 67-72 [PMID: 11929147]

12 **Chung SH**, Lindholm B, Lee HB. Influence of initial nutritional status on continuous ambulatory peritoneal dialysis patient survival. *Perit Dial Int* 2000; **20**: 19-26 [PMID: 10716579]

13 **Dong J**, Li YJ, Lu XH, Gan HP, Zuo L, Wang HY. Correlations of lean body mass with nutritional indicators and mortality in patients on peritoneal dialysis. *Kidney Int* 2008; **73**: 334-340 [PMID: 18033246 DOI: 10.1038/sj.ki.5002644]

14 **Huang JW**, Lien YC, Wu HY, Yen CJ, Pan CC, Hung TW, Su CT, Chiang CK, Cheng HT, Hung KY. Lean body mass predicts long-term survival in Chinese patients on peritoneal dialysis. *PLoS One* 2013; **8**: e54976 [PMID: 23372806 DOI: 10.1371/journal.pone.0054976]

15 **Lo WK,** Prowant BF, Gamboa SB, Moore HL, Nolph KD. How reproducible is daily creatinine recovery in chronic peritoneal dialysis? *Perit Dial Int* 1994; **14:** 286-288

16 **Mitch WE**, Walser M. A proposed mechanism for reduced creatinine excretion in severe chronic renal failure. *Nephron* 1978; **21**: 248-254 [PMID: 714198 DOI: 10.1159/000181400]

17 **Tzamaloukas AH**, Braun M, Malhotra D, Murata GH. Estimated versus predicted creatinine generation as an indicator of compliance with the prescribed dose of continuous peritoneal dialysis. *Int J Artif Organs* 1996; **19**: 151-155 [PMID: 8675358]

18 **Fitch CD**, Sinton DW. A study of creatine metabolism in diseases causing muscle wasting. *J Clin Invest* 1964; **43**: 444-452 [PMID: 14135495 DOI: 10.1172/JCI104929]

19 **Picou D**, Reeds PJ, Jackson A, Poulter N. The measurement of muscle mass in children using [15N]creatine. *Pediatr Res* 1976; **10**: 184-188 [PMID: 765941 DOI: 10.1203/00006450-197603000-00008]

20 **Xu Z**, Gabaldon D, Wiggins B, Rondon-Berrios H, VanderJagt DJ, Tzamaloukas AH. Increase in serum creatinine in a patient on continuous peritoneal dialysis: potential mechanisms and management. *Adv Perit Dial* 2012; **28**: 32-36 [PMID: 23311210]

21 **Lew SQ**, Watson JA. Urea and creatinine generation and removal in a pregnant patient receiving peritoneal dialysis. *Adv Perit Dial* 1992; **8**: 131-135 [PMID: 1361769]

22 **BLEILER RE**, SCHEDL HP. Creatinine excretion: variability and relationships to diet and body size. *J Lab Clin Med* 1962; **59**: 945-955 [PMID: 13869979]

23 **Cockcroft DW**, Gault MH. Prediction of creatinine clearance from serum creatinine. *Nephron* 1976; **16**: 31-41 [PMID: 1244564 DOI: 10.1159/000180580]

24 **Keen M**, Lipps B, Gotch F. The measured creatinine generation rate in CAPD suggests only 78% of prescribed dialysis is delivered. *Adv Perit Dial* 1993; **9**: 73-75 [PMID: 8105967]

25 **Warren PJ**, Brandes JC. Compliance with the peritoneal dialysis prescription is poor. *J Am Soc Nephrol* 1994; **4**: 1627-1629 [PMID: 8025237]

26 **Nolph KD**, Twardowski ZJ, Khanna R, Moore HL, Prowant BF. Predicted and measured daily creatinine production in CAPD: identifying noncompliance. *Perit Dial Int* 1995; **15**: 22-25 [PMID: 7734556]

27 **Fischer A**, Bock A, Brunner FP. Three consecutive day collection of dialysate and urine to identify non-compliance in CAPD patients. *Nephrol Dial Transplant* 1997; **12**: 570-573 [PMID: 9075143 DOI: 10.1093/ndt/12.3.570]

28 **Tzamaloukas AH**. Pharmacokinetic analysis of creatinine generation discrepancy as an index of noncompliance in CAPD. *Adv Perit Dial* 1996; **12**: 61-65 [PMID: 8865875]

29 **Blake PG**, Spanner E, McMurray S, Lindsay RM, Ferguson E. Comparison of measured and predicted creatinine excretion is an unreliable index of compliance in PD patients. *Perit Dial Int* 1996; **16**: 147-153 [PMID: 9147548]

30 **Burkart JM**, Bleyer AJ, Jordan JR, Zeigler NC. An elevated ratio of measured to predicted creatinine production in CAPD patients is not a sensitive predictor of noncompliance with the dialysis prescription. *Perit Dial Int* 1996; **16**: 142-146 [PMID: 9147547]

31 **Bernardini J**, Piraino B. Measuring compliance with prescribed exchanges in CAPD and CCPD patients. *Perit Dial Int* 1997; **17**: 338-342 [PMID: 9284459]

32 **Szeto CC**, Lai KN, Wong TY, Law MC, Li PK. Measured-to-predicted creatinine generation ratio increases with time and decline in residual renal function in continuous ambulatory peritoneal dialysis. *Am J Kidney Dis* 1999; **34**: 235-241 [PMID: 10430968 DOI: 10.1016/S0272-6386(99)70349-5]

33 **Fox L**, Tzamaloukas AH, Murata GH. Metabolic differences between persistent and routine peritonitis in CAPD. *Adv Perit Dial* 1992; **8**: 346-350 [PMID: 1361820]

34 **Lo WK**, Prowant BF, Moore HL, Gamboa SB, Nolph KD, Flynn MA, Londeree B, Keshaviah P, Emerson P. Comparison of different measurements of lean body mass in normal individuals and in chronic peritoneal dialysis patients. *Am J Kidney Dis* 1994; **23**: 74-85 [PMID: 8285201 DOI: 10.1016/S0272-6386(12)80815-8]

35 **Negri AL**, Veron D, Fraga A, Arrizurieta E, Zucchini A, Zanchetta JR. Lean body mass estimation by densitometry and creatinine kinetics in chronic peritoneal dialysis patients. *Perit Dial Int* 2000; **20**: 575-576 [PMID: 11117251]

36 **Bhatla B**, Moore H, Emerson P, Keshaviah P, Prowant B, Nolph KD, Singh A. Lean body mass estimation by creatinine kinetics, bioimpedance, and dual energy x-ray absorptiometry in patients on continuous ambulatory peritoneal dialysis. *ASAIO J* 1995; **41**: M442-M446 [PMID: 8573842 DOI: 10.1097/00002480-199507000-00048]

37 **Nielsen PK**, Ladefoged J, Olgaard K. Lean body mass by Dual Energy X-ray Absorptiometry (DEXA) and by urine and dialysate creatinine recovery in CAPD and pre-dialysis patients compared to normal subjects. *Adv Perit Dial* 1994; **10**: 99-103 [PMID: 7999874]

38 **de Fijter WM**, de Fijter CW, Oe PL, ter Wee PM, Donker AJ. Assessment of total body water and lean body mass from anthropometry, Watson formula, creatinine kinetics, and body electrical impedance compared with antipyrine kinetics in peritoneal dialysis patients. *Nephrol Dial Transplant* 1997; **12**: 151-156 [PMID: 9027791 DOI: 10.1093/ndt/12.1.151]

39 **Johansson AC**, Attman PO, Haraldsson B. Creatinine generation rate and lean body mass: a critical analysis in peritoneal dialysis patients. *Kidney Int* 1997; **51**: 855-859 [PMID: 9067921 DOI: 10.1038/ki.1997.120]

40 **Szeto CC**, Kong J, Wu AK, Wong TY, Wang AY, Li PK. The role of lean body mass as a nutritional index in Chinese peritoneal dialysis patients--comparison of creatinine kinetics method and anthropometric method. *Perit Dial Int* 2000; **20**: 708-714 [PMID: 11216564]

41 **Tzamaloukas AH**, Murata GH. Lean body mass calculation by creatinine kinetics in CAPD. Is it only a measure of somatic nutrition? *Perit Dial Int* 2000; **20**: 351-352 [PMID: 10898059]

42 **Negri AL**, Barone R, Veron D, Fraga A, Arrizurieta E, Zucchini A, Zanchetta JR. Lean mass estimation by creatinine kinetics and dual-energy x-ray absorptiometry in peritoneal dialysis. *Nephron Clin Pract* 2003; **95**: c9-14 [PMID: 14520016 DOI: 10.1159/000073013]

**P- Reviewer:** Friedman EA, Onuigbo M, Yorioka N, Stavroulopoulos A

**S- Editor:** Song XX **L- Editor:** **E- Editor:**

**Specialty type:** Urology and nephrology

**Country of origin:** United States

**Peer-review report classification**

Grade A (Excellent): A

Grade B (Very good): B

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

**Table 1 Patient characteristics**

|  |  |  |  |
| --- | --- | --- | --- |
|  | Two clearancestudies | Three clearancestudies | Four clearancestudies |
| Patient number | 166 | 84 | 44 |
| Age at onset of peritoneal dialysis, years | 52 ± 15 | 51 ± 16 | 51 ± 18 |
| Male (%) | 94 (56.6) | 46 (54.8) | 26 (59.1) |
| Female (%) | 72 (43.4) | 38 (45.2) | 18 (40.9) |
| Diabetic nephropathy (%) | 73 (44.0) | 36 (42.9) | 17 (38.6) |

**Table 2 Creatinine excretion in patients with two studies**

|  |  |  |  |
| --- | --- | --- | --- |
| Variable | 1st clearancestudy | 2nd clearancestudy | *P* value |
| PD duration, mo | 9.2 ± 15.2 | 17.4 ± 15.8 |  |
| VU, L/24-h | 0.54 ± 0.63 | 0.40 ± 0.53 | < 0.001 |
| VD, L/24-h | 11.3 ± 3.2 | 12.1 ± 3.6 | NS |
| Kt/V urea, weekly | 2.30 ± 0.62 | 2.12 ± 0.03 | 0.003 |
| CCr, L/1.73 m2, weekly | 77.9 ± 32.1 | 67.9 ± 18.2 | 0.002 |
| SUN, mg/dL | 49.7 ± 15.1 | 49.4 ± 16.2 | NS |
| [Cr]S, mg/dL | 9.1 ± 3.3 | 10.1 ± 3.4 | 0.001 |
| EXCr U, mg/24-h | 406 ± 337 | 286 ± 350 | 0.003 |
| EXCr D, mg/24-h | 680 ± 337 | 769 ± 390 | < 0.001 |
| EXCr T, mg/24-h | 1087 ± 470 | 1055 ± 421 | NS |

PD: Peritoneal dialysis; NS: Not significant; VU: Urine volume; VD: Drained volume of spent dialysate; Kt/V urea: Fractional urea clearance, weekly; CCr: Weekly renal plus peritoneal creatinine clearance; SUN: Serum urea nitrogen; [Cr]S: Serum creatinine concentration; EXCr D: Creatinine excretion in spent dialysate; EXCr U: Creatinine excretion in urine; EXCr T: Total creatinine excretion in urine plus dialysate; BSA: Body surface area.

**Table 3 Creatinine excretion in patients with three studies**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Variable | 1st clearancestudy | 2nd clearancestudy | 3rd clearancestudy | *P* value |
| PD duration, mo | 8.6 ± 7.8 | 16.8 ± 11.6 | 24.7 ± 16.3 |  |
| VU, L/24-h | 0.58 ± 0.66 | 0.45 ± 0.59 | 0.38 ± 0.50 | 0.0001 |
| VD, L/24-h | 11.5 ± 4.0 | 11.8 ± 3.7 | 12.4 ± 3.7 | NS |
| Kt/V urea, weekly | 2.28 ± 0.65 | 2.14 ± 0.58 | 2.12 ± 0.63 | 0.0245 |
| CCr, L/1.73 m2, weekly | 79.3 ± 35.6 | 71.4 ± 27.8 | 68.0 ± 26.9 | 0.0335 |
| SUN, mg/dL | 50.4 ± 18.5 | 49.5 ± 17.9 | 49.2 ± 19.2 | NS |
| [Cr]S, mg/dL | 9.5 ± 3.5 | 9.8 ± 3.4 | 10.1 ± 3.3 | 0.0066 |
| EXCr U, mg/24-h | 418 ± 404 | 370 ± 425 | 286 ± 362 | < 0.0001 |
| EXCr D, mg/24-h | 731 ± 379 | 767 ± 396 | 779 ± 382 | NS1 |
| EXCr T, mg/24-h | 1149 ± 416 | 1137 ± 454 | 1065 ± 442 | 0.0087 |

1Statistical trend (*P* = 0.0895). PD: Peritoneal dialysis; NS: Not significant; VU: Urine volume; VD: Drained volume of spent dialysate; Kt/V urea: Fractional urea clearance, weekly; CCr: Weekly renal plus peritoneal creatinine clearance; SUN: Serum urea nitrogen; [Cr]S: Serum creatinine concentration; EXCr D: Creatinine excretion in spent dialysate; EXCr U: Creatinine excretion in urine; EXCr T: Total creatinine excretion in urine plus dialysate; BSA: Body surface area.

**Table 4 Creatinine excretion in patients with four clearance studies**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Variable | 1st clearancestudy | 2ndclearancestudy | 3rdclearancestudy | 4thclearancestudy | *P* value |
| PD duration, mo | 8.1 ± 12.6 | 16.5 ± 4.4 | 24.5 ± 16.3 | 31.9 ± 16.8 |  |
| VU, L/24-h  | 0.54 ± 0.55 | 0.41 ± 0.49 | 0.33 ± 0.40 | 0.29 ± 0.42 | < 0.0001 |
| VD, L/24-h | 11.8 ± 3.9 | 12.2 ± 3.6 | 12.2 ± 3.5 | 12.5 ± 3.2 | NS |
| Kt/V urea, weekly | 2.27 ± 0.65 | 2.15 ± 0.56 | 2.13 ± 0.54 | 2.10 ± 0.55 | 0.0356 |
| CCr, L/1.73 m2, weekly | 77.5 ± 29.7 | 70.4 ± 28.5 | 68.5 ± 25.7 | 66.1 ± 22.1 | 0.0238 |
| SUN, mg/dL | 49.8 ± 16.7 | 49.5 ± 15.4 | 49.2 ± 15.3 | 49.0 ± 13.5 | NS |
| [Cr]S, mg/dL | 9.8 ± 3.6 | 10.2 ± 3.7 | 10.8 ± 3.8 | 10.8 ± 3.6 | 0.0009 |
| EXCr U, mg/24-h | 411 ± 438 | 382 ± 460 | 272 ± 345 | 282 ± 481 | 0.0011 |
| EXCr D, mg/24-h | 755 ± 406 | 788 ± 424 | 808 ± 438 | 853 ± 398 | 0.0021 |
| EXCr T, mg/24-h | 1166 ± 440 | 1170 ± 495 | 1080 ± 455 | 1135 ± 521 | NS |

PD: Peritoneal dialysis; NS: Not significant; VU: Urine volume; VD: Drained volume of spent dialysate; Kt/V urea: Fractional urea clearance, weekly; CCr: Weekly renal plus peritoneal creatinine clearance; SUN: Serum urea nitrogen; [Cr]S: Serum creatinine concentration; EXCr D: Creatinine excretion in spent dialysate; EXCr U: Creatinine excretion in urine; EXCr T: Total creatinine excretion in urine plus dialysate; BSA: Body surface area.

**Table 5 Number (percent) of studies with creatinine excretion deviating from baseline by <15% and ≥ 15%**

|  |  |  |  |
| --- | --- | --- | --- |
| Study | < 15% fromthe 1st study | ≥ 15% abovethe 1st study | ≥ 15% belowthe 1st study |
| Second | 90 (54.2%) | 41 (24.7%) | 35 (21.1%) |
| Third | 40 (47.6%) | 28 (33.3%) | 16 (19.1%) |
| Fourth | 24 (54.5%) | 11 (25.0%) | 9 (20.5%) |